We recently published a list of BofA’s Top 10 Growth Stocks with The Fastest Projected EPS Growth Rates. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best BofA’s top growth stocks with the fastest projected EPS growth rates.
For the stock market, if there’s one thing that can be said with some certainty, it’s that earnings and revenue growth drives share price performance. This is because a firm’s stock price is a reflection of investor estimates of its future market potential. Firms that are believed to gain market share in the future often see their share price surge in the present as investors tailor their portfolios to try to get an early position in some of the biggest names of tomorrow.
In fact, we don’t have to dig too deep to see this principle in action. The clearest example of it is in the stock of the AI chips company that’s Wall Street’s favorite AI stock so far. Its stock is up 199% year to date, 235% over the past twelve months, and 887% since the start of 2023. While all these returns are something that most–if not all–company executives would give an arm and a leg for, to see our principle in action, we’ll have to dig deeper into the 887% share price gain.
Narrowing down our analysis to this stock’s performance in 2023–from the start and to the end of the year–its shares gained 239%. During the first half, they gained 189.5% and during Q1, the stock was up 90%. So, the shares’ performance in Q2 has proven crucial as the starting point of a rally that has so far yielded an 887% share price appreciation. During Q2, the stock was up 52%, driven by the fact that on May 24th, 2023 (during the Q1FY24 earnings), the firm’s CEO stunned investors when he shared that “A trillion dollars of installed global data center infrastructure will transition from general purpose to accelerated computing as companies race to apply generative AI into every product, service and business process.”
This meant that CEO Jensen Huang believed that in the future, businesses would spend as much as $1 trillion on his company’s products. Investors were ecstatic and they piled into the company to send its shares soaring by 24.6% between May 19th and May 26th. In this company’s case, the CEO’s optimism was also met by cold, hard results. During the same Q1, the firm’s data center business division revenue jumped by 14% annually, in a sign that foretold the growth story of the next quarters. Mind you, this fiscal Q1 was only the second quarter following OpenAI’s public ChatGPT release, so the AI wave that solidified in Q4 2024 was in its infancy.
These hard results saw the firm annually grow its revenue by 101%, 206%, 265%, 262%, and 122% in its Q2FY24, Q3FY24, Q4FY24, Q1FY25, and Q2FY25, respectively. The top line growth has been accompanied by bottom line profits also jumping by triple digit percentages in all of the quarters. The highest reading was for Q2FY24 when its non-GAAP net income jumped by 843% year-over-year.
Thus, it’s safe to say that growth is rewarded by the stock market. Yet, the high investor expectations for growth stocks also mean that they are punished harder in case they fail to meet expectations. Research from the University of Michigan analyzed data for 13 years covering consensus earnings forecasts, quarterly earnings, stock prices, market to book ratio, and price to earnings ratio to check whether growth and value stocks perform similarly if they fail to meet earnings expectations.
Their results show that growth stocks tend to fall more than value stocks when it comes to negative earnings surprises. The researchers add that the underperformance is typically before the earnings are announced since growth stocks typically preannounce their negative earnings surprise. A descriptive analysis of their data also shows that cumulative stock returns for the days between two earnings cycles are higher for low growth stocks over high growth stocks. For the lowest growth stocks, the cumulative returns for all firms analyzed were 0.66%, while those for firms with negative and positive earnings surprises were -3.57% and 5.44%, respectively. For the high growth stocks, cumulative returns for all firms were -0.58%, and the returns for those with negative and positive earnings surprises were -7.32% and 6.32%, respectively.
The research concisely sums up the potential of investing in growth stocks and the accompanying risks. Returning to our GPU designer, while right now it’s at the center of the AI buzz, back in 2017 and 2018, it was at the center of the Bitcoin rush since gaming GPUs could also be used to mine cryptocurrencies. However, between mid-December 2017 and mid-December 2018, Bitcoin’s price dropped by 83%. For the firm’s quarter that ended in January 2019, this led to its gaming GPU revenue dropping by 45% year-over-year and 46% sequentially. This was because the crypto sector had over ordered GPUs, but as Bitcoin prices fell, mining became unprofitable and the over-ordering led to a glut in the market. Looking at the firm’s post split stock price, this led to the stock falling by 53% between October and the end of December 2018.
Our Methodology
To make our list of BofA’s top growth stock picks, we used the bank’s latest list of stocks that are rated Buy, have an EPS surprise rating, and the highest projected growth rates for the next five years. The stocks were ranked by their projected EPS growth rates.
For these stocks, we have also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders In Q2 2024: 100
Projected EPS Growth Rate: 50.6%
Eli Lilly and Company (NYSE:LLY) is a mega pharmaceutical company that sells diabetes, obesity, and cancer medicines. These expose it to some of the hottest markets of the pharma industry and its success in the obesity market has also translated into share price tailwinds. LLY shares are up 53% year-to-date However, with weight loss drugs now being a key part of its hypothesis, any threat from competitors means that the shares are hit hard. This was the case between mid-July and early August when LLY stock bled 19% after investors reacted to favorable weight loss drug developments from Roche and Viking Therapeutics. To ensure that it remains a leading player in the market, Eli Lilly and Company (NYSE:LLY) is currently working on Orforglipron, which is cheaper and easier to produce than current treatments. This is key especially as generic weight loss drugs can further dilute the market.
Baron Funds mentioned Eli Lilly and Company (NYSE:LLY) in its Q2 2024 investor letter. Here is what the fund said:
“In biopharmaceuticals, we remain bullish on the market opportunity for new diabetes and obesity medicines. In June at a medical meeting, the principal investigators of the SURMOUNT-OSA trial presented the full data which demonstrated that Eli Lilly and Company’s Tirzepatide reduced obstructive sleep apnea in adults with obesity by up to 62.8%, and up to 51.5% of participants met the criteria for disease resolution. This impressive data set paves the way for Tirzepatide to be used as a treatment for obstructive sleep apnea in overweight and obese individuals.”
Overall, LLY ranks 4th on our list of best BofA’s top growth stocks with the fastest projected EPS growth rates. LLY is one of the top stocks with the highest consensus earnings growth according to BofA. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.